Pacific Edge eyes final US milestone within year

Pacific Edge eyes final US milestone within year
Gavin Evans
By Gavin Evans Aug 1 (BusinessDesk) - Pacific Edge says it may achieve the key third element for reimbursement by private and public US health insurers for its Cxbladder cancer diagnostic tests within a year. The firm has already been granted a national price for its tests and two of its products have been granted national product codes for the US. Studies of Cxbladder published in European Urology and the New Zealand Medical Journal this year, and the products’ inclusion this month in the US National Comprehensive Cancer Network Guide...

More Services

Latest cap raise values Sharesies at $750m
Markets

Latest cap raise values Sharesies at $750m

In its eighth raise since 2017, Sharesies values its shares at $205 apiece.

Pattrick Smellie 10 Oct 2025
Two MC partners quit for specialist firm
Services

Two MC partners quit for specialist firm

Cuncannon now has a broader commercial offering. 

Staff reporters 06 Oct 2025
DB Breweries appoints new MD
Retail

DB Breweries appoints new MD

Peter Hart returns to NZ.

Victoria Young 01 Oct 2025
2degrees earnings show cash momentum
Services

2degrees earnings show cash momentum

Non-cash costs mask strong operating earnings and cashflow.

Pattrick Smellie 24 Sep 2025